# EDGAR Filing Document

**Accession Number:** 0000811641
**File Stem:** 0001437749-26-017045
**Filing Date:** 2026-5
**Character Count:** 93192
**Document Hash:** 6b6c5d775ac6fd8391c98793c00b850c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001437749-26-017045.hdr.sgml**: 20260514

**ACCESSION NUMBER**: 0001437749-26-017045

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 78

**CONFORMED PERIOD OF REPORT**: 20260331

**FILED AS OF DATE**: 20260514

**DATE AS OF CHANGE**: 20260514

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** IMMUCELL CORP /DE/
- **CENTRAL INDEX KEY:** 0000811641
- **STANDARD INDUSTRIAL CLASSIFICATION:** IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 010382980
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-12934
- **FILM NUMBER:** 26978843

**BUSINESS ADDRESS:**
- **STREET 1:** 56 EVERGREEN DR
- **CITY:** PORTLAND
- **STATE:** ME
- **ZIP:** 04103
- **BUSINESS PHONE:** 2078782770

**MAIL ADDRESS:**
- **STREET 1:** 56 EVERGREEN DRIVE
- **CITY:** PORTLAND
- **STATE:** ME
- **ZIP:** 04103

?xml version='1.0' encoding='ASCII'? iccc20260331_10q.htm

[**Table of Contents**](#toc)

------

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 10-Q**

**(Mark One)**

**☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the quarterly period ended March 31, 2026**

OR

**☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the transition period from _________________ to _____________________**

**<u>001-12934</u>**

**(Commission file number)**

![lgo01.jpg](lgo01.jpg)

**<u>ImmuCell Corporation</u>**

**(Exact name of registrant as specified in its charter)**

---

| | |
|:---|:---|
| Delaware | 01-0382980 |
| (State of Incorporation) | (I.R.S. Employer<br> Identification No.) |

---

---

| | |
|:---|:---|
| 56 Evergreen Drive, Portland, ME | 04103 |
| (Address of principal executive office) | (Zip Code) |

---

<u>(207) 878-2770</u>

(Registrant's telephone number)

Securities registered pursuant to Section 12(b) of the Exchange Act:

---

| | |
|:---|:---|
| **Title of each class** | **Name of each exchange on which registered** |
| Common Stock, $0.10 par value per share ICCC | The Nasdaq Capital Market |

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The number of shares of the registrant's common stock outstanding as of May 1, 2026 was 9,046,799.

------

[**Table of Contents**](#toc)

**ImmuCell Corporation**

**TABLE OF CONTENTS**

**March 31, 2026**

---

| | | |
|:---|:---|:---|
| [Forward-Looking Statements](#fwdlookingstmts) | [Forward-Looking Statements](#fwdlookingstmts) | [Forward-Looking Statements](#fwdlookingstmts) |
| [**<u>PART I: FINANCIAL INFORMATION</u>**](#part1) | [**<u>PART I: FINANCIAL INFORMATION</u>**](#part1) | [**<u>PART I: FINANCIAL INFORMATION</u>**](#part1) |
| [<u>ITEM 1.</u>](#financialstmts) | [<u>Condensed Unaudited Financial Statements</u>](#financialstmts) |  |
|  | [<u>Condensed Balance Sheets as of March 31, 2026 and December</u> <u>31, 2025</u>](#bs) | [2](#bs) |
|  | [<u>Condensed Statements of Income for the three months ended March 31, 2026 and 2025</u>](#ops) | [3](#ops) |
|  | [<u>Condensed Statements of Stockholders</u><u>'</u> <u>Equity for the three months ended March 31, 2026 and 2025</u>](#equity)  | [4](#equity) |
|  | [<u>Condensed Statements of Cash Flows for the three months ended March 31, 2026 and 2025</u>](#cf) | [5](#cf)-[6](#cfcontinued) |
|  | [<u>Notes to Condensed Unaudited Financial Statements</u>](#notes) | [7](#notes)-[15](#endnotes) |
| [<u>ITEM 2.</u>](#mda) | [<u>Management</u><u>'</u><u>s Discussion and Analysis of Financial Condition and Results of Operations</u>](#mda) | [16](#mda)-[18](#mdaend) |
| [<u>ITEM 3.</u>](#quant) | [<u>Quantitative and Qualitative Disclosures about Market Risk</u>](#quant) | [19](#quant) |
| [<u>ITEM 4.</u>](#controls) | [<u>Controls and Procedures</u>](#controls) | [19](#controls) |
| [**<u>PART II: OTHER INFORMATION</u>**](#part2) | [**<u>PART II: OTHER INFORMATION</u>**](#part2) | [**<u>PART II: OTHER INFORMATION</u>**](#part2) |
| [ITEM 1.](#p2item1) | [Legal Proceedings](#p2item1) | [19](#p2item1) |
| [ITEM 1A](#p2item1a). | [Risk Factors](#p2item1a) | [19](#p2item1a) |
| [ITEM 2.](#p2item2) | [Unregistered Sales of Equity Securities and Use of Proceeds](#p2item2) | [19](#p2item2) |
| [ITEM 3.](#p2item3) | [Defaults Upon Senior Securities](#p2item3) | [19](#p2item3) |
| [ITEM 4.](#p2item4) | [Mine Safety Disclosures](#p2item4) | [19](#p2item4) |
| [ITEM 5.](#p2item5) | [Other Information](#p2item5) | [19](#p2item5) |
| [ITEM 6.](#p2item6) | [Exhibits](#p2item6) | [20](#p2item6) |
|  | [<u>Signature</u>](#signatures) | [21](#signatures) |

---

------

[**Table of Contents**](#toc)

**Forward-Looking Statements**

This Quarterly Report contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements can be identified by the fact that they do not relate strictly to historical or current facts and will often include words such as "expects", "may", "anticipates", "aims", "intends", "would", "could", "should", "will", "plans", "believes", "estimates", "targets", "projects", "forecasts", "seeks" and similar words and expressions. Such statements include, but are not limited to, any forward-looking statements relating to: our plans, goals and strategies for our business; projections of future financial or operational performance; future demand for our products, including the First Defense<sup>®</sup> product line; the scope, timing, and costs of ongoing and future product development work and commercialization of our products; future regulatory requirements relating to our products; future expense ratios and margins; estimates of useful lives of equipment; cost recoveries on Re-Tain<sup>®</sup> equipment no longer in service; and any other statements that are not historical facts. projections about depreciation expense and its impact on income for book and tax return purposes; and any other statements that are not historical facts. These statements are intended to provide management's current expectation of future events as of the date of this earnings release, are based on management's estimates, projections, beliefs and assumptions as of the date hereof; and are not guarantees of future performance. Such statements involve known and unknown risks and uncertainties that may cause the Company's actual results, financial or operational performance or achievements to be materially different from those expressed or implied by these forward-looking statements, including, but not limited to, those risks and uncertainties relating to: difficulties or delays in development, testing, regulatory approval, production and marketing of our products, competition within our anticipated product markets, customer acceptance of our new and existing products, product performance, alignment between our manufacturing resources and product demand (including the consequences of backlogs), uncertainty associated with the timing and volume of customer orders as we come out of a prolonged backlog, adverse impacts of supply chain disruptions on our operations and customer and supplier relationships, commercial and operational risks relating to our current and planned expansion of production capacity, and other risks and uncertainties detailed from time to time in filings we make with the Securities and Exchange Commission (SEC), including our Quarterly Reports on Form 10-Q, our Annual Reports on Form 10-K and our Current Reports on Form 8-K. Such statements involve risks and uncertainties and are based on our current expectations, but actual results may differ materially due to various factors, including the risk factors summarized under **PART II: OTHER INFORMATION, ITEM 1A-RISK FACTORS** and uncertainties otherwise referred to in this Quarterly Report. In addition, there can be no assurance that future risks, uncertainties or developments affecting us will be those that we anticipate. We undertake no obligation to update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1

------

[**Table of Contents**](#toc)

**ImmuCell Corporation**

**Part 1. FINANCIAL INFORMATION**

**ITEM 1. CONDENSED UNAUDITED FINANCIAL STATEMENTS**

**CONDENSED BALANCE SHEETS**

**(Unaudited)**

---

| | | |
|:---|:---|:---|
|  | ***As of*** | ***As of*** |
|  | ***March 31,*** | ***December 31,*** |
|  | ***2026*** | ***2025*** |
| **ASSETS** |  |  |
| **CURRENT ASSETS:** |  |  |
| Cash and cash equivalents | $6812637 | $3806831 |
| Trade accounts receivable | 2694418 | 3419009 |
| Inventory | 8673752 | 9267369 |
| Prepaid expenses and other current assets | 681215 | 451673 |
| Total current assets | 18862022 | 16944882 |
| Property, plant and equipment, net | 20777226 | 21074694 |
| Operating lease right-of-use asset | 4339415 | 4379628 |
| Goodwill | 95557 | 95557 |
| Other assets | 34154 | 37686 |
| **TOTAL ASSETS** | $44108374 | $42532447 |
| **LIABILITIES AND STOCKHOLDERS' EQUITY** |  |  |
| **CURRENT LIABILITIES:** |  |  |
| Current portion of debt obligations | $1628540 | $1610185 |
| Current portion of operating lease liability | 88586 | 85489 |
| Accounts payable and accrued expenses | 2195950 | 2282583 |
| Total current liabilities | 3913076 | 3978257 |
| **LONG-TERM LIABILITIES:** |  |  |
| Debt obligations, net of current portion | 7073726 | 7488922 |
| Operating lease liability, net of current portion | 3986532 | 4009788 |
| Total long-term liabilities | 11060258 | 11498710 |
| **TOTAL LIABILITIES** | 14973334 | 15476967 |
| **COMMITMENTS AND CONTINGENCIES** |  |  |
| **STOCKHOLDERS' EQUITY:** |  |  |
| Common stock, $0.10 par value per share, 15,000,000 shares authorized and 9,105,622 shares issued and 9,046,799 and 9,045,851 shares outstanding, as of March 31, 2026 and December 31, 2025, respectively. | 910563 | 910563 |
| Additional paid-in capital | 41680837 | 41479430 |
| Accumulated deficit | (13262146) | (15203753) |
| Treasury stock, at cost, 58,823 and 59,771 shares as of March 31, 2026 and December 31, 2025, respectively | (194214) | (130760) |
| **TOTAL STOCKHOLDERS' EQUITY** | 29135040 | 27055480 |
| **TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY** | $44108374 | $42532447 |

---

*The accompanying notes are an integral part of these condensed unaudited financial statements.*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2

------

[**Table of Contents**](#toc)

**ImmuCell Corporation**

**CONDENSED STATEMENTS OF INCOME**

**(Unaudited)**

---

| | | |
|:---|:---|:---|
|  | ***Three Months Ended March 31,*** | ***Three Months Ended March 31,*** |
|  | ***2026*** | ***2025*** |
| Product sales | $10357295 | $8067174 |
| Costs of goods sold | 5699851 | 4713202 |
| Gross profit | 4657444 | 3353972 |
| Sales and marketing expenses | 1232763 | 856658 |
| Administrative expenses | 1137677 | 622843 |
| Product development expenses | 317688 | 756847 |
| Operating expenses | 2688128 | 2236348 |
| **NET OPERATING INCOME** | 1969316 | 1117624 |
| Other (expenses) income, net | (15187) | 331263 |
| **INCOME BEFORE INCOME TAXES** | 1954129 | 1448887 |
| Income tax expense | 12522 | 1904 |
| **NET INCOME** | $1941607 | $1446983 |
| Basic weighted average common shares outstanding | 9045977 | 8980602 |
| Basic net income per share | $0.21 | $0.16 |
| Diluted weighted average common shares outstanding | 9045977 | 8980602 |
| Diluted net income per share | $0.21 | $0.16 |

---

*The accompanying notes are an integral part of these condensed unaudited financial statements.*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3

------

[**Table of Contents**](#toc)

**ImmuCell Corporation**

**CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY**

**(Unaudited)**

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  | ***Common Stock*** | ***Common Stock*** | ***Common Stock*** |  | ***Treasury Stock*** | ***Treasury Stock*** |  |
|  |  |  | ***Additional*** |  |  |  | ***Total*** |
|  |  |  | ***paid-in*** | ***Accumulated*** |  |  | ***Stockholders'*** |
|  | ***Shares*** | ***Amount*** | ***capital*** | ***Deficit*** | ***Shares*** | ***Amount*** | ***Equity*** |
| Balance, December 31, 2025 | 9105622 | $910563 | $41479430 | $(15203753) | 59771 | $(130760) | $27055480 |
| Net income | *—* |  |  | 1941607 | *—* |  | 1941607 |
| Exercise of stock options |  |  | 63458 |  | (948) | (63454) | 4 |
| Stock-based compensation | *—* |  | 137949 |  | *—* |  | 137949 |
| Balance March 31, 2026 | 9105622 | $910563 | $41680837 | $(13262146) | 58823 | $(194214) | $29135040 |
| Balance, December 31, 2024 | 9042392 | $904240 | $40916155 | $(14163726) | 63301 | $(138482) | $27518187 |
| Net income | *—* |  |  | 1446983 | *—* |  | 1446983 |
| At-The-Market Offering of common stock, net of $42,975 of issuance fees | 3532 | 353 | (23894) |  |  |  | (23541) |
| Stock-based compensation | *—* |  | 52215 |  | *—* |  | 52215 |
| Balance, March 31, 2025 | 9045924 | $904593 | $40944476 | $(12716743) | 63301 | $(138482) | $28993844 |

---

*The accompanying notes are an integral part of these condensed unaudited financial statements.*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4

------

[**Table of Contents**](#toc)

**ImmuCell Corporation**

**CONDENSED STATEMENTS OF CASH FLOWS**

**(Unaudited)**

---

| | | |
|:---|:---|:---|
|  | ***Three Months Ended March 31,*** | ***Three Months Ended March 31,*** |
|  | ***2026*** | ***2025*** |
| **CASH FLOWS FROM OPERATING ACTIVITIES:** |  |  |
| Net income | $1941607 | $1446983 |
| Adjustments to reconcile net income to net cash provided by operating activities: |  |  |
| Depreciation | 528294 | 671191 |
| Amortization of intangible assets |  | 4776 |
| Amortization of debt issuance costs and debt discounts | 3158 | 10806 |
| Stock-based compensation | 137949 | 52215 |
| (Gain) loss on disposal of property, plant and equipment | (4264) | 4865 |
| Non-cash rent expense (benefit) | 20054 | (37998) |
| Changes in: |  |  |
| Trade accounts receivable | 724591 | 424708 |
| Inventory | 593617 | (244743) |
| Prepaid expenses and other current assets | (229542) | (215715) |
| Other assets | 3532 | (12049) |
| Accounts payable and accrued expenses | (145965) | (531203) |
| Net cash provided by operating activities | 3573031 | 1573836 |
| **CASH FLOWS FROM INVESTING ACTIVITIES:** |  |  |
| Purchase of property, plant and equipment | (177230) | (329050) |
| Proceeds from sale of property, plant and equipment | 10000 |  |
| Net cash used for investing activities | (167230) | (329050) |
| **CASH FLOWS FROM FINANCING ACTIVITIES:** |  |  |
| Repayments on bank debt | (399999) | (380106) |
| Proceeds from At-The-Market Offering |  | 19434 |
| Payments of equity issuance fees |  | (42975) |
| Proceeds from exercise of stock options | 4 |  |
| Net cash used for financing activities | (399995) | (403647) |
| **NET INCREASE IN CASH AND CASH EQUIVALENTS** | 3005806 | 841139 |
| **BEGINNING CASH AND CASH EQUIVALENTS** | 3806831 | 3758232 |
| **ENDING CASH AND CASH EQUIVALENTS** | $6812637 | $4599371 |

---

*The accompanying notes are an integral part of these condensed unaudited financial statements.*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 5

------

[**Table of Contents**](#toc)

**ImmuCell Corporation**

**CONDENSED STATEMENTS OF CASH FLOWS**

**SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION**

**(Unaudited)**

---

| | | |
|:---|:---|:---|
|  | ***Three Months Ended March 31,*** | ***Three Months Ended March 31,*** |
|  | ***2026*** | ***2025*** |
| **CASH PAID FOR:** |  |  |
| Income taxes | $10609 | $— |
| Interest | $97240 | $117857 |
| **NON-CASH ACTIVITIES:** |  |  |
| Change in capital expenditures incurred, but not paid | $(59332) | $(17246) |

---

*The accompanying notes are an integral part of these condensed unaudited financial statements.*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 6

------

[**Table of Contents**](#toc)

**ImmuCell Corporation**

**Notes to Condensed Unaudited Financial Statements**

***1.* BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES**

**Nature of Operations**

ImmuCell Corporation, founded in *1982* and a SEC-registered public company since *1987,* is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Our primary product line, First Defense<sup>®</sup>, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. In the United States, First Defense<sup>®</sup> products are regulated as veterinary biologics by the U.S. Department of Agriculture's Center for Veterinary Biologics under the Virus-Serum-Toxin Act. In Canada, products are regulated by the Canadian Food Inspection Agency and in other countries, the products are regulated by similar agencies. Certain product formats are marketed as feed supplements regulated by the U.S. Food and Drug Administration under the Federal Food, Drug, and Cosmetic Act. References to ImmuCell ("the Company") throughout this document are made using the *first* person notations of "we", "us" and "our". See our Annual Report on Form *10*-K for the year ended *December 31, 2025* for further information about our company and strategy.

**Seasonality of Sales**

Sales of the First Defense<sup>®</sup> product line are seasonal, with higher sales expected during the *first* quarter of the calendar year, largely driven by the beef calving season, which runs primarily from *January* to *April,* unlike the dairy industry where operations generally calve year-round. Warm and dry weather conditions *may* reduce the producers' perceived need for disease prevention products such as the First Defense<sup>®</sup> product line. However, heat stress on calves caused by extremely hot summer weather and cold stress during the winter months can increase the incidence of scours and the need for our products.

**Basis of Presentation**

The accompanying condensed unaudited financial statements have been prepared in accordance with (i) United States generally accepted accounting principles ("U.S. GAAP") for interim financial information and (ii) the instructions to Form *10*-Q and Article *8* of Regulation S-*X.* In the opinion of our management, our condensed unaudited financial statements and accompanying notes (the "Financial Statements") include all normal recurring adjustments that are necessary for the fair statement of the interim periods presented. Interim results of operations are *not* necessarily indicative of results for the full year. The Financial Statements should be read in conjunction with our audited financial statements (and notes thereto) in our Annual Report on Form *10*-K for the year ended *December 31, 2025.*

**Estimates and Assumptions**

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Although we regularly assess these estimates, actual amounts could differ from those estimates and are subject to change in the near term. Changes in estimates are recorded during the period in which they become known. Significant estimates include our valuation of inventory, deferred tax assets, and the impairment of long-lived assets.

In connection with the idle status of certain property, plant and equipment, net, (related to the repurposing of certain equipment previously utilized in the manufacturing of Re-Tain<sup>®</sup>), we reassessed prior estimates of the useful lives of that manufacturing equipment. Because the equipment had seen such limited use during the period since installation, we increased the estimated remaining useful lives on certain equipment by a weighted average of five years effective *January 1, 2026.* The effect of this change in estimate for the *three* months ended *March 31, 2026* was a $0.1 million decrease to depreciation expense included in costs of goods sold, and an increase in operating income and net income of $0.1 million, or $0.01 per both basic and diluted share.

See Note *5,* "Property, Plant and Equipment" for further information.

**Significant Accounting Policies**

The accounting policies used in preparing these condensed financial statements are the same as those described in our Annual Report on Form *10*-K for the year ended *December 31, 2025.* Unless otherwise indicated, all references to years are to our fiscal years, which end on *December 31.*

**Accounting Pronouncement *Not* Yet Adopted**

In *November* of *2024,* the FASB issued ASU *2024*-*03, Disaggregation of Income Statement Expenses*, to provide disaggregated disclosures of specific expense categories underlying all relevant income statement expense line items on an annual and interim basis. The disclosure requirements will be applied on a prospective basis, with the option to apply it retrospectively. The effective date for the standard is for fiscal years beginning after *December 15, 2026,* and interim periods within fiscal years beginning after *December 15, 2027.* Early adoption is permitted. We are evaluating ASU *2024*-*03* to determine its impact on our financial statements.

During the *three* months ended *March 31, 2026,* there were *no* other newly issued or newly applicable accounting pronouncements that had, or are expected to have, a material impact on the Company's Financial Statements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *7*

------

[**Table of Contents**](#toc)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ImmuCell Corporation

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Notes to Condensed Unaudited Financial Statements (continued)

***2.* TRADE ACCOUNTS RECEIVABLE AND CONCENTRATION OF RISK**

***Allowance for Credit and Sales Losses***

As of *March 31, 2026* or *December 31, 2025* we determined that no allowance for credit losses or product returns was necessary. We consider a broad range of information to estimate credit losses. Historically, we have experienced a very low level of credit loss expense, and most of our trade receivables are collected by the due date or within a few days of the due date. We anticipate *no* future events or conditions that would impact our ability to collect our accounts receivable. Because of the generally short duration from the balance sheet date to the date of collection, our collection rate is *not* expected to be significantly impacted by events occurring after the balance sheet date. *No* accounts receivable were written off during the *three* month periods ended *March 31, 2026* or *2025.*

***Concentration of Risk***

Concentration of credit risk with respect to accounts receivable is principally limited to certain customers to whom we make substantial sales. To reduce risk, we routinely assess the financial strength of our customers and, therefore, believe that our accounts receivable credit risk exposure is limited. We maintain an allowance for potential credit losses when deemed necessary, but historically we have *not* experienced significant credit losses related to an individual customer or groups of customers in any particular industry or geographic area.

Sales to significant customers that amounted to *10* percent or more of total product sales are detailed in the following table:

---

| | | |
|:---|:---|:---|
|  | ***Three Months Ended March 31,*** | ***Three Months Ended March 31,*** |
|  | ***2026*** | ***2025*** |
| Company A | 35% | 44% |
| Company B | 25% | 27% |
| Company C | *\** | 10% |
| Total | 60% | 81% |

---

\*The amount is less than *10* percent.

Trade accounts receivable due from significant customers that amounted to *10* percent or more of our total trade accounts receivable are detailed in the following table:

---

| | | |
|:---|:---|:---|
|  | ***As of*** | ***As of*** |
|  | ***March 31, 2026*** | ***December 31, 2025*** |
| Company A | 43% | 45% |
| Company B | 22% | 24% |
| Company C | 11% | *\** |
| Total | 76% | 69% |

---

\*The amount is less than *10* percent.

***3.* INVENTORY**

Inventory consisted of the following:

---

| | | |
|:---|:---|:---|
|  | ***As of*** | ***As of*** |
|  | ***March 31, 2026*** | ***December 31, 2025*** |
| Raw materials | $1523003 | $1650778 |
| Work-in-process, net | 5400833 | 5748889 |
| Finished goods | 1749916 | 1867702 |
| Total | $8673752 | $9267369 |

---

***4.* PREPAID EXPENSES AND OTHER CURRENT ASSETS**

Prepaid expenses and other current assets consisted of the following:

---

| | | |
|:---|:---|:---|
|  | ***As of*** | ***As of*** |
|  | ***March 31, 2026*** | ***December 31, 2025*** |
| Prepaid expenses | $647488 | $420496 |
| Other receivables | 33727 | 31177 |
| Total | $681215 | $451673 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *8*

------

[**Table of Contents**](#toc)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ImmuCell Corporation

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Notes to Condensed Unaudited Financial Statements (continued)

***5.* PROPERTY, PLANT AND EQUIPMENT, NET**

As of both *March 31, 2026* and *December 31, 2025,* property, plant and equipment, net includes approximately $12,300,000 of idle assets, which primarily relate to *one* of our manufacturing facilities that was previously utilized for Re-Tain<sup>®</sup> that we now plan to refit for use in producing First Defense<sup>®</sup> products. In connection with the idle status of the assets, we reassessed the useful lives of the manufacturing equipment. See Note *1,* "Basis of Presentation and Significant Accounting Policies" for further information. We are monitoring these assets for impairment. No impairment expense was recognized during the *three* months ended *March 31, 2026* or *2025.*

Depreciation expense was $528,294 and $671,191 during the *three* months ended *March 31, 2026* and *2025,* respectively.

***6.* ACCOUNTS PAYABLE AND ACCRUED EXPENSES**

Accounts payable and accrued expenses consisted of the following:

---

| | | |
|:---|:---|:---|
|  | ***As of*** | ***As of*** |
|  | ***March 31, 2026*** | ***December 31, 2025*** |
| Accounts payable – trade | $935095 | $792217 |
| Accounts payable – capital | 63401 | 4069 |
| Accrued payroll | 801364 | 1032479 |
| Accrued professional fees | 67336 | 113414 |
| Accrued other | 320147 | 333710 |
| Income tax payable | 8607 | 6694 |
| Total | $2195950 | $2282583 |

---

***7.* Fair Value Measurements**

The carrying value and estimated fair value of financial instruments are reflected in the following tables:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  |  |  | **As of March 31, 2026** | **As of March 31, 2026** | **As of March 31, 2026** | **As of March 31, 2026** |
|  | **Carrying** | **Fair** | **Quoted Prices** | **Significant** |  |  |
|  | **Value** | **Value** | **in Active** | **Other** | **Significant** |  |
|  |  |  | **Markets for** | **Observable** | **Observable** |  |
|  |  |  | **Identical Assets** | **Inputs** | **Inputs** |  |
|  |  |  | **(Level 1)** | **(Level 2)** | **(Level 3)** | **Total** |
| Assets: |  |  |  |  |  |  |
| Cash and money market accounts<sup>(1)</sup> | $6812637 | $6812637 | $6812637 | $— | $— | $6812637 |
| Liabilities: |  |  |  |  |  |  |
| Bank debt<sup>(2)</sup> | $8702266 | $8116358 | $— | $8116358 | $— | $8116358 |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  |  |  | **As of December 31, 2025** | **As of December 31, 2025** | **As of December 31, 2025** | **As of December 31, 2025** |
|  | **Carrying** | **Fair** | **Quoted Prices** | **Significant** |  |  |
|  | **Value** | **Value** | **in Active** | **Other** | **Significant** |  |
|  |  |  | **Markets for** | **Observable** | **Observable** |  |
|  |  |  | **Identical Assets** | **Inputs** | **Inputs** |  |
|  |  |  | **(Level 1)** | **(Level 2)** | **(Level 3)** | **Total** |
| Assets: |  |  |  |  |  |  |
| Cash and money market accounts<sup>(1)</sup> | $3806831 | $3806831 | $3806831 | $— | $— | $3806831 |
| Liabilities: |  |  |  |  |  |  |
| Bank debt<sup>(2)</sup> | $9099107 | $8457433 | $— | $8457433 | $— | $8457433 |

---

<sup>(*1*)</sup> Cash and cash equivalents are stated at nominal value, which equals fair value. A portion of our cash and cash equivalents is invested in money market accounts. The fair value of these investments is based on their closing published net asset value.

<sup>(*2*)</sup> Due to inflation and the changing interest rate environment, the carrying values of our fixed rate bank debt as of *March 31, 2026* and *December 31, 2025* differed from their fair market values. The amount outstanding under our bank debt facilities is measured at carrying value in our accompanying balance sheets.

We evaluate assets and liabilities subject to fair value measurements on a recurring and nonrecurring basis to determine the appropriate level at which to classify them for each reporting period. Some nonfinancial assets are measured at fair value only in certain circumstances, including the event of impairment.

We assess the levels of assets and liabilities at each measurement date, and transfers between levels are recognized on the actual date of the event or change in circumstances that caused the transfer in accordance with our accounting policy regarding the recognition of transfers between levels of the fair value hierarchy. During the *three* months ended *March 31, 2026* and *2025*, there were no transfers between levels.

As of *March 31, 2026* and *December 31, 2025,* the carrying amounts of accounts receivable, inventory, prepaid expenses and other current assets, other assets, accounts payable and accrued expenses approximate fair value because of their short-term nature.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *9*

------

[**Table of Contents**](#toc)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ImmuCell Corporation

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Notes to Condensed Unaudited Financial Statements (continued)

***8.* BANK DEBT**

**Loans *#1* and *#2***: During the *first* quarter of *2020,* we closed on a debt financing with Maine Community Bank (formerly known as Gorham Savings Bank) (MCB) aggregating $8,600,000, which was comprised of a $5,100,000 mortgage note (Loan *#1*) that bears interest at a fixed rate of 3.50% per annum (with a 10-year term and 25-year amortization schedule and a balloon principal payment of $3,145,888 due during the *first* quarter of *2030*) and a $3,500,000 note (Loan *#2*) that bears interest at a fixed rate of 3.50% per annum (with a 7-year term and amortization schedule). The proceeds from the *2020* debt refinancing were used to repay all bank debt outstanding at the time of closing and to provide some additional working capital. During the *first* quarter of *2022,* we closed on an additional $2,000,000 in mortgage debt, which bears interest at the fixed rate of 3.58% per annum. This was accomplished through an amendment of the original mortgage note (Loan *#1*) that increased the then outstanding principal balance from $4,233,957 to $6,233,957 bearing interest at the blended fixed rate of 3.53% per annum. This increased the balloon payment from $3,145,888 to $3,687,751 and extended the due date of the balloon payment from the *first* quarter of *2030* to the *first* quarter of *2032.*

**Loan *#3***: During the *second* quarter of *2020,* we received a loan from the Maine Technology Institute (MTI) in the aggregate principal amount of $500,000. The *first* 2.25 years of this loan were interest-free with no interest accrual or required principal payments. Beginning during the *fourth* quarter of *2022,* Loan *#3* became subject to quarterly principal and interest payments at a fixed rate of 5% per annum over the final five years of the loan, through the *third* quarter of *2027* if *not* repaid before then.

**Loan *#4***: During the *fourth* quarter of *2020,* we closed on a $1,500,000 note with MCB that bears interest at a fixed rate of 3.50% per annum (with a 7-year term and amortization schedule). Proceeds of $624,167 were used to prepay a portion of the outstanding principal on our mortgage note (Loan *#1*), which reduced the outstanding balance to 80% of the most recent appraised value of the property securing the debt, which allowed MCB to release the $1,400,000 that had been held in escrow. The remaining proceeds were available for general working capital purposes.

**Loan *#5***: On *June 30, 2021,* we executed definitive agreements covering a *second* loan from the MTI in the aggregate principal amount of $400,000, proceeds from which were received in *July* of *2021.* The *first* two years of this loan were interest-free with no interest accrual or required principal payments. Principal and interest payments at a fixed rate of 5% per annum are due quarterly over the final 5.5 years of the loan, beginning during the *third* quarter of *2023* and continuing through the *fourth* quarter of *2028* if *not* repaid before then.

**Loan *#6:*** During the *third* quarter of *2023,* we closed on a $2,000,000 term loan bearing interest at a fixed rate of 7% per annum from MCB. The Finance Authority of Maine (FAME) provided $1,000,000 of loan insurance to MCB. This loan was repayable under a 7-year amortization schedule with a balloon payment of $1,285,029 due during the *third* quarter of *2026.* This loan was refinanced during the year ended *December 31, 2025,* utilizing the proceeds from Loan *#8* discussed below.

**Loan *#7:*** Also during the *third* quarter of *2023,* we closed on a $1,000,000 term loan bearing interest at a fixed rate of 8% per annum from FAME. The loan was repayable under a 7-year amortization schedule with a balloon payment of $649,267 due during the *third* quarter of *2026.* This loan was refinanced during the year ended *December 31, 2025,* utilizing the proceeds from Loan *#8* discussed below.

**Loan *#8:*** During the year ended *December 31, 2025,* we refinanced some of our bank debt. The principal amount of $1,525,852 outstanding as of the closing date under Loan *#6* and the principal amount of $768,209 outstanding as of the closing date under Loan *#7* were both refinanced into *one* MCB loan with a principal amount of $2,327,119 bearing interest at a fixed rate of 6.5% per annum, a reduction from both Loan *#6* and Loan *#7.* This refinancing also removed the balloon principal payments that were due in *July* of *2026* under both Loans *#6* and *#7.* Principal and interest payments under the new loan of $45,637 per month are due over a five-year term ending during the *third* quarter of *2030.*

Loans *#1, #2, #4,* and *#8* are secured by liens on substantially all of our assets and are subject to certain restrictions and annual financial covenants. Loans *#3* and *#5* are unsecured and subordinated to our indebtedness to MCB. Failure to make timely payments of principal and interest, or otherwise to comply with the terms of the agreements of Loans *#3* and *#5,* would entitle the MTI to accelerate the maturity of such debt and demand repayment in full. These loans *may* be prepaid without penalty at any time.

Principal payments (net of debt issuance and debt discount costs) due under bank loans outstanding as of *March 31, 2026* (excluding our $1,000,000 line of credit) are reflected in the following table by the year that payments are due:

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  | ***2026*** | ***2027*** | ***2028*** | ***2029*** | ***2030*** | ***Thereafter*** | ***Total*** |
| Loans #1-#8 | $1222386 | $1242436 | $821163 | $782667 | $642988 | $4035161 | $8746801 |
| Debt issuance cost<sup>(1)</sup> | (7093) | (6969) | (5062) | (5063) | (4442) | (4321) | (32950) |
| Debt discount cost<sup>(1)</sup> | (1998) | (2664) | (2663) | (2663) | (1597) |  | (11585) |
| Total | $1213295 | $1232803 | $813438 | $774941 | $636949 | $4030840 | $8702266 |

---

<sup>(*1*)</sup> The amortization of these debt issuance costs and debt discount costs is being recorded as a component of interest expense, included in other (expenses) income, net, and is being amortized on a straight-line basis over the underlying terms of the notes.

We maintain a $1,000,000 line of credit (LOC) with MCB, which is available, as needed, through *September 11, 2026.* Interest on borrowings against the LOC is variable at the National Prime Rate per annum. There was no outstanding balance under this LOC as of *March 31, 2026* or *December 31, 2025*.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *10*

------

[**Table of Contents**](#toc)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ImmuCell Corporation

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Notes to Condensed Unaudited Financial Statements (continued)

***9.* COMMITMENTS AND CONTINGENCIES**

**Litigation and Regulatory**

Our bylaws, as amended, in effect provide that we will indemnify our officers and directors against any liability arising from their responsibilities as officers and directors to the maximum extent permitted by Delaware law. In addition, we make similar indemnity undertakings with each director and executive officer through a separate indemnification agreement with that director or officer. The maximum payment that we *may* be required to make under such provisions is theoretically unlimited and is impossible to determine. We maintain directors' and officers' liability insurance, which *may* provide us reimbursement for payments made to, or on behalf of, officers and directors pursuant to the indemnification provisions. Our indemnification obligations were grandfathered under the provisions of Codification Topic *460, Guarantees*. Accordingly, we have recorded no liability for such obligations as of *March 31, 2026* or *December 31, 2025*. Since our incorporation, we have had *no* occasion to make any indemnification payment to any of our officers or directors for any reason.

The development, manufacturing and marketing of animal health and nutrition products entails an inherent risk that liability claims will be asserted against us during the normal course of business. We are aware of *no* such claims against us as of the time of this filing on *May 14, 2026.* We believe that we have reasonable levels of liability insurance to support our operations.

We enter into agreements with *third* parties in the ordinary course of business under which we are obligated to indemnify such *third* parties from and against various risks and losses. The precise terms of such indemnities vary with the nature of the agreement. In some cases those obligations *may* be theoretically unlimited. We have not incurred material expenses in discharging any of these indemnification obligations and based on our analysis of the nature of the risks involved, we believe that the fair value of the liabilities potentially arising under these agreements is minimal. Accordingly, we recorded no liabilities for such obligations as of *March 31, 2026* or *December 31, 2025*.

**Employee Compensation**

Upon retirement from the Company during *January 2026,* Mr. Brigham (our former President and Chief Executive Officer), was paid $239,369 for all earned and unused paid time off, as well as $100,000 related to a retention and performance bonus in equal amounts. Both amounts were included in accounts payable and accrued expenses as of *December 31, 2025.*

As of *September 29, 2025,* we entered into an employment agreement with Mr. te Boekhorst (effective upon commencement of employment as Company President and Chief Executive Officer) under which he will receive an annual base salary of $450,000. He also will be entitled to earn annual cash bonuses of up to an additional $400,000 per year subject to the Company having achieved financial improvement targets from the prior year, as set in advance by our Board of Directors or its Compensation and Stock Option Committee of our Board of Directors (the "Committee"). The targets for *2026* have been set based on the board approved budget in the *first* quarter of *2026.*

Effective as of *January 27, 2026,* we entered into new employment agreements with Timothy C. Fiori, the Company's Chief Financial Officer, and Bobbi Jo Brockmann, the Company's Senior Vice President of Sales and Marketing. Pursuant to the new employment agreements, Mr. Fiori will be compensated at an annual base salary of $315,000 and Ms. Brockmann will be compensated at an annual base salary of $300,000. Starting with the fiscal year ending *December 31, 2026,* each of Mr. Fiori and Ms. Brockmann will be eligible to earn a formulaic annual cash bonus if various preset financial and strategic targets are achieved. The target cash bonus amount is 50% of base salary (potentially higher if all targets are exceeded). The financial and strategic targets for *2026* were approved by the Committee. Per the employment agreements, the annual financial and strategic targets thereafter will be set each year by our CEO in consultation with the Committee; for targets that are qualitative in nature, the extent to which the qualitative target was achieved is to be determined each year by the Committee. These agreements also include provisions for potential severance payments, which are dependent on the nature in which employment terminates.

As with other incentive-based compensation, payouts of annual cash bonuses are subject to possible retroactive claw back if and to the extent mandated by Company policy or applicable laws or listing requirements.

**Other Commitments**

In addition to the commitments discussed above, we had committed $76,000 to increase our production capacity for the First Defense<sup>®</sup> product line, $1,733,000 to the purchase of inventory, $419,000 to information technology services, $312,000 to cold storage services, and $723,000 for other obligations as of *March 31, 2026*.

***10.* STOCKHOLDERS**' **EQUITY**

**Common Stock Issuances**

In the *three*-month period ended *March 31, 2025,* the Company sold shares pursuant to the At-The-Market (ATM) agreement (net of legal, accounting, sales commissions and other fees) for net proceeds of ($23,541). There was no ATM activity in the *three*-month period ended *March 31,* 2026.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 11

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ImmuCell Corporation

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Notes to Condensed Unaudited Financial Statements (continued)

**Stock Option Plans**

On *November 7, 2025,* the Board of Directors adopted a new 2025 Stock Option and Incentive Plan (the *"2025* Plan"), under which employees, directors and other service providers *may* be granted options to purchase shares of the Company's common stock at *no* less than fair market value on the date of grant. The Board further revised the *2025* Plan on *March 26, 2026* and *April 7, 2026,* including revising the number of shares from 500,000 to 650,000, as well as revisions to the change in control provisions, minimum vesting period and exercise period for retiring directors. As set forth in the Company's definitive proxy statement for the *June 11, 2026* Annual Meeting of Stockholders, the Board submitted the *2025* Plan, as so revised, to stockholders for approval at that meeting. If for any reason the *2025* Plan is *not* approved by vote of the Company's stockholders within *12* months after the date of the Plan's adoption by the Board, then with limited exceptions all stock options previously granted under that Plan would, by their terms and consistent with Nasdaq Listing Rules, lapse and become non-exercisable.

In the *first* quarter of *2026,* Michael F. Brigham surrendered 24,052 shares of previously owned common stock in the Company in exchange for the exercise of 25,000 incentive stock options. There were no stock options exercised in the *three* month period ended *March 31, 2025.*

On *January 27, 2026,* we granted stock options to purchase 220,000 shares of the Company's common stock to *two* executive officers of the Company. Such options have a grant-date fair value of $3.51 per share and vest ratably over three years from date of grant. We record stock-based compensation expense on a straight-line basis for all stock options. On *January 27, 2026,* we granted an additional stock option to purchase 109,500 shares of the Company's common stock to the Company's President and CEO, contingent on achieving certain internal performance metrics. Such option has a grant-date fair value of $3.51 and vests only if and when the Company's net operating income for *four* consecutive calendar quarters equals or exceeds 300% of the Company's audited net operating income for its *2025* fiscal year. As of *March 31, 2026,* we believe that the vesting of the option is probable.

The fair value of stock options, including performance-based stock options, is estimated on the grant date using a Black-Scholes option-pricing model. We recorded compensation expense pertaining to stock-based awards of $137,949 and $52,215 during the *three* months ended *March 31, 2026* and *2025,* respectively. The increase in stock-compensation expense is due to grants to our executive officers beginning in *April 2025.* 

***11.* Net Income Per Share**

Basic net income per share is computed by dividing net income by the weighted average common shares outstanding during the period. The computation of diluted net income per share is similar to the computation of basic net income per share, except that the weighted average common shares outstanding includes the assumed exercise of in-the-money options and contingently issuable shares that would be issuable if the end of the reporting period was the end of the contingency period, unless the effect is anti-dilutive. We use the treasury stock method, which assumes that proceeds, including cash received from the exercise of employee stock options and the average unrecognized compensation expense for unvested awards during the period, would be used to purchase the Company's common stock at the average market price during the period.

---

| | | |
|:---|:---|:---|
|  | ***Three Months Ended March 31,*** | ***Three Months Ended March 31,*** |
|  | ***2026*** | ***2025*** |
| Net income attributable to stockholders | $1941607 | $1446983 |
| Weighted average common shares outstanding - Basic | 9045977 | 8980602 |
| Dilutive impact of share-based compensation awards |  |  |
| Weighted average common shares outstanding - Diluted | 9045977 | 8980602 |
| Net income per share: |  |  |
| Basic | $0.21 | $0.16 |
| Diluted | $0.21 | $0.16 |

---

Outstanding stock options that were *not* included in this calculation because the effect would be anti-dilutive amounted to 1,076,260 and 641,000 during the *three* months ended *March 31, 2026* and *2025,* respectively.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *12*

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ImmuCell Corporation

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Notes to Condensed Unaudited Financial Statements (continued)

***12.* REVENUE**&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

We primarily offer the First Defense<sup>®</sup> product line to dairy and beef producers to prevent scours in newborn calves. This line offers *two* distinct platforms: i) veterinary biologics providing scours protection with USDA-approved claims against *E.coli*, coronavirus and rotavirus and ii) functional feed products delivering concentrated bioactive colostrum proteins. Generally, our products are promoted to veterinarians as well as dairy and beef producers by our sales team and then sold through distributors.

We have determined that each unit within each purchase order we receive from our customers is distinct, can be used on its own, and is *not* combined with another promise. As such, each unit constitutes a distinct performance obligation. The transaction price is determined based on the pricing noted within each written contract or provided to customers via standard price lists and with payments typically due in full within *30* days of invoicing. Our contracts do *not* include significant financing components.

We recognize revenue at a point in time, when we invoice at shipment, which is when the customer assumes legal title and we have the right to payment.

There were *no* material changes between the allocation and timing of revenue recognition during the *three* months ended *March 31, 2026* or *2025*.

The following table presents our product sales disaggregated by geographic area:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | ***Three Months Ended March 31,*** | ***Three Months Ended March 31,*** | ***Three Months Ended March 31,*** | ***Three Months Ended March 31,*** |
|  | ***2026*** | ***Percent*** | ***2025*** | ***Percent*** |
| United States | $9734045 | 94% | $7174890 | 89% |
| Other | 623250 | 6% | 892284 | 11% |
| Total Product Sales | $10357295 | 100% | $8067174 | 100% |

---

All trade receivables on our balance sheet date are from contracts with customers. As of *January 1, 2025,* trade accounts receivable (all of which relates to contracts with customers) totaled $3,771,133. We do *not* have any contract assets for which we have satisfied the performance obligation, but do *not* yet have the right to payment. We do *not* have any contract liabilities such as upfront customer payments or deferred revenue. We incur *no* material costs to obtain or fulfill contracts with customers.

***13.* OTHER (EXPENSES) INCOME, NET**

Other (expenses) income, net consisted of the following:

---

| | | |
|:---|:---|:---|
|  | ***Three Months Ended March 31,*** | ***Three Months Ended March 31,*** |
|  | ***2026*** | ***2025*** |
| Interest expense<sup>(1)</sup> | $(99675) | $(127928) |
| Interest income | 44367 | 37469 |
| Other income | 35857 |  |
| Gain (loss) on disposal of property, plant and equipment | 4264 | (4865) |
| Insurance recoveries<sup>(2)</sup> |  | 426587 |
| &nbsp;&nbsp;&nbsp; Total | $(15187) | $331263 |

---

<sup>(*1*)</sup> Interest expense includes amortization of debt issuance and debt discount costs of $3,158 and $10,806 during the *three* months ended *March 31, 2026* and *2025*, respectively.

<sup>(*2*)</sup> The income from insurance recoveries resulted from claim benefits paid to us during the *first* quarter of *2025* under our business interruption policy related to product contamination losses incurred during late *2022* and through early *2024.* This recovery does *not* include the $250,000 received on this claim during the *third* quarter of *2023.*

***14.* INCOME TAXES**

Our income tax expense aggregated $12,522 and $1,904 (amounting to less than 1% of our income before income taxes) during the *three* months ended *March 31, 2026* and *2025*, respectively.

During the *second* quarter of *2018,* we assessed our historical and near-term future profitability and recorded $563,252 in non-cash income tax expense to create a full valuation allowance against our net deferred tax assets (which consist largely of net operating loss carryforwards and federal and state credits) based on applicable accounting standards and practices. At that time, we had incurred a net loss for *six* consecutive quarters, had *not* been profitable on a year-to-date basis since the *nine* months ended *September 30, 2017* and projected additional net losses for some period going forward before returning to profitability. Should future profitability be realized at an adequate level, we would be able to release this valuation allowance (resulting in a non-cash income tax benefit) and realize these deferred tax assets before they expire. We will continue to assess the need for the valuation allowance at each quarter and, in the event that actual results differ from these estimates, or we adjust these estimates in future periods, we *may* need to adjust our valuation allowance. Currently, we adjust the valuation allowance at the end of each quarter to reduce the value of our net deferred tax assets to zero.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 13

------

[**Table of Contents**](#toc)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ImmuCell Corporation

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Notes to Condensed Unaudited Financial Statements (continued)

***15.* SEGMENT INFORMATION**

Our business operations (being the development, manufacture and sale of products that improve the health and productivity of dairy and beef cattle) are described in Note *1,* "Basis of Presentation and Significant Accounting Policies". Our chief operating decision-maker (CODM), our President and CEO, regularly evaluates two operating segments: i) Scours and ii) Mastitis for purposes of deciding how to allocate resources and assess performance. Our CODM primarily evaluates performance based on product sales as well as net operating income (loss). *No* operating segments have been aggregated; therefore, our two operating segments are the Company's two reportable segments.

*Scours* segment - consists of the First Defense<sup>®</sup> product line. The core technology underlying the Scours segment is focused on polyclonal antibodies.

*Mastitis* segment - includes our CMT product line, consisting of reagents and equipment used for rapid cow-side testing to identify mastitic quarters by detecting elevated somatic cell counts. This segment also includes our Re-Tain<sup>®</sup> product in development for the treatment of subclinical mastitis based on the bacteriocin nisin. On *December 23, 2025,* we made the decision to cease our focus on obtaining FDA approval of Re-Tain<sup>®</sup> and instead continue the stability and investigational testing related to Re-Tain<sup>®</sup>.

*Other* - includes unallocated administrative and overhead expenses and other products.

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | ***Three Months Ended March 31, 2026*** | ***Three Months Ended March 31, 2026*** | ***Three Months Ended March 31, 2026*** | ***Three Months Ended March 31, 2026*** |
|  | ***Scours*** | ***Mastitis*** | ***Other*** | ***Total*** |
| Product sales | $10307775 | $49520 | $— | $10357295 |
| Costs of goods sold | 5667751 | 32100 |  | 5699851 |
| Gross profit | 4640024 | 17420 |  | 4657444 |
| Sales and marketing expenses | 1225960 | 6803 |  | 1232763 |
| Administrative expenses |  |  | 1137677 | 1137677 |
| Product development expenses | 98093 | 168399 | 51196 | 317688 |
| Operating expenses | 1324053 | 175202 | 1188873 | 2688128 |
| **NET OPERATING INCOME (LOSS)** | $3315971 | $(157782) | $(1188873) | $1969316 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | ***Three Months Ended March 31, 2025*** | ***Three Months Ended March 31, 2025*** | ***Three Months Ended March 31, 2025*** | ***Three Months Ended March 31, 2025*** |
|  | ***Scours*** | ***Mastitis*** | ***Other*** | ***Total*** |
| Product sales | $8028486 | $38688 | $— | $8067174 |
| Costs of goods sold | 4674543 | 38659 |  | 4713202 |
| Gross profit | 3353943 | 29 |  | 3353972 |
| Sales and marketing expenses | 787137 | 69521 |  | 856658 |
| Administrative expenses |  |  | 622843 | 622843 |
| Product development expenses | 93485 | 628912 | 34450 | 756847 |
| Operating expenses | 880622 | 698433 | 657293 | 2236348 |
| **NET OPERATING INCOME (LOSS)** | $2473321 | $(698404) | $(657293) | $1117624 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | ***Scours*** | ***Mastitis*** | ***Other*** | ***Total*** |
| Total Assets as of March 31, 2026<sup>(1)</sup> | $36886606 | $228107 | $6993661 | $44108374 |
| Total Assets as of March 31, 2025 | $24486105 | $16340874 | $4794600 | $45621579 |
| Depreciation and amortization expense during the three months ended March 31, 2026 | $521175 | $— | $10277 | $531452 |
| Depreciation and amortization expense during the three months ended March 31, 2025 | $352522 | $314659 | $19592 | $686773 |
| Capital Expenditures during the three months ended March 31, 2026 | $158732 | $8526 | $9972 | $177230 |
| Capital Expenditures during the three months ended March 31, 2025 | $322377 | $6673 | $— | $329050 |

---

<sup>(*1*)</sup> As of *March 31, 2026,* property, plant and equipment, net includes approximately $12,300,000 of idle assets, which primarily related to *one* of our manufacturing facilities that was previously utilized for Re-Tain<sup>®</sup> that we now plan to refit for use in producing First Defense<sup>®</sup> products.

***16.* RELATED PARTY TRANSACTIONS**

David S. Tomsche (Chair of our Board of Directors) is a controlling owner of Leedstone Inc., a domestic distributor of our products (the First Defense® product line and CMT). His affiliated company purchased $433,518 and $250,513 of products from us during the *three*-month periods ended *March 31, 2026* and *2025,* respectively, all on terms consistent with those offered to other distributors of similar status. Our accounts receivable (subject to standard and customary payment terms) due from this affiliated company aggregated $5,520 and $0 as of *March 31, 2026* and *December 31, 2025,* respectively.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *14*

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ImmuCell Corporation

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Notes to Condensed Unaudited Financial Statements (continued)

***17.* SUBSEQUENT EVENTS**

We have evaluated subsequent events through the time of filing on the date we have issued this Quarterly Report on Form *10*-Q.

Subsequent to *March 31, 2026,* the Company entered into a lease agreement for *two* vehicles used by the sales team. The leases are *not* material to the Company's financial position, results of operations, or cash flows.

On *May 8, 2026,* the Company and Norbrook Laboratories Limited (incorporated and registered in Northern Ireland (Norbrook)) entered into a Settlement Deed to resolve and release any and all claims arising out of or relating to an underlying *2019* development Services and Commercial Supply Agreement between the *two* companies. As previously reported, that agreement expired *March 31, 2026.* Under the Settlement Deed, Norbrook has agreed to pay the Company the sum of $2,000,000. The Settlement Deed is governed by Northern Ireland law, includes undertakings regarding confidentiality, and does *not* constitute an admission of liability or wrongdoing on the part of either party.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *15*

------

[**Table of Contents**](#toc)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ImmuCell Corporation

**ITEM 2 - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**

The following discussion and analysis of our financial condition and results of operations should be read together with our condensed unaudited financial statements and the related notes and other financial information included in this Quarterly Report on Form 10-Q (Quarterly Report). Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. One should review the Forward-Looking Statements for a discussion of some of the important factors that could cause actual results to differ materially from the anticipated results, objectives or expectations described in or implied by the forward-looking statements contained in the following discussion and analysis.

**Overview**

ImmuCell Corporation, founded in 1982 and a SEC-registered public company since 1987, is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves.

**Change in Accounting Estimate**

In connection with the idle status of certain property, plant and equipment, net, (related to the repurposing of certain equipment previously utilized in the manufacturing of Re-Tain<sup>®</sup>), we reassessed prior estimates of the useful lives of that manufacturing equipment. Because the equipment had seen such limited use during the period since installation, we increased the estimated remaining useful lives on certain equipment by a weighted average of five years effective January 1, 2026. The effect of this change in estimate for the three months ended March 31, 2026 was a $0.1 million decrease to depreciation expense included in costs of goods sold, and an increase in operating income and net income of $0.1 million, or $0.01 per both basic and diluted share.

See Note 5, "Property, Plant and Equipment" of the Notes to Condensed Unaudited Financial Statements included in Part I, Item 1 of this Form 10-Q for further information.

**Seasonality of Sales**

Sales of the First Defense<sup>®</sup> product line are seasonal, with higher sales expected during the first quarter of the calendar year, largely driven by the beef calving season, which runs primarily from January to April, unlike the dairy industry where operations generally calve year-round. Warm and dry weather conditions may reduce the producers' perceived need for disease prevention products such as the First Defense<sup>®</sup> product line. However, heat stress on calves caused by extremely hot summer weather and cold stress during the winter months can increase the incidence of scours and the need for our products.

**Results of Operations for the Three Months Ended March 31, 2026, Compared with the Three Months Ended March 31, 2025**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Increase/(Decrease)** | **Increase/(Decrease)** |
|  | **2026** | **2025** | **Amount** | **Percent** |
| Product sales | $10357295 | $8067174 | $2290121 | 28.4% |
| Costs of goods sold | 5699851 | 4713202 | 986649 | 20.9% |
| Gross profit | 4657444 | 3353972 | 1303472 | 38.9% |
| Sales and marketing expenses | 1232763 | 856658 | 376105 | 43.9% |
| Administrative expenses | 1137677 | 622843 | 514834 | 82.7% |
| Product development expenses | 317688 | 756847 | (439159) | (58.0)% |
| Operating expenses | 2688128 | 2236348 | 451780 | 20.2% |
| **NET OPERATING INCOME** | 1969316 | 1117624 | 851692 | 76.2% |
| Other (expenses) income, net | (15187) | 331263 | (346450) | (104.6)% |
| **INCOME BEFORE INCOME TAXES** | 1954129 | 1448887 | 505242 | 34.9% |
| Income tax expense | 12522 | 1904 | 10618 | 557.7% |
| **NET INCOME** | $1941607 | $1446983 | $494624 | 34.2% |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 16

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ImmuCell Corporation

*Product Sales*

Sales of the First Defense<sup>®</sup> product line made up 99.5% of our total sales during the three months ended March 31, 2026 and 2025. We also sell our own CMT, which is used to detect somatic cell counts in milk. Sales of CMT aggregated approximately 0.5% of our total product sales during the periods reported.

Product sales during the three months ended March 31, 2026 were $10.4 million representing a 28.4%, or $2.3 million, increase over product sales of $8.1 million during the three months ended March 31, 2025. The increase was primarily due to higher sales volumes of Tri-Shield<sup>®</sup> and Dual Force<sup>®</sup> combined with year-over-year product price increases across most product lines.

Domestic sales during the three months ended March 31, 2026 increased by 35.7% (to $9.7 million), and international sales decreased by 30.2% (to $0.6 million), in comparison to the three months ended March 31, 2025. International sales aggregated 6.0% and 11.1% of total sales during the three months ended March 31, 2026 and 2025, respectively.

*Costs of Goods Sold*

Costs of goods sold during the three months ended March 31, 2026 were $5.7 million representing a 20.9%, or $1.0 million, increase over costs of goods sold of $4.7 million during the three months ended March 31, 2025. The increase was primarily due to higher sales of First Defense<sup>®</sup> combined with a shift of $0.3 million of costs associated with the former Re-Tain<sup>®</sup> manufacturing facility from product development expense to costs of goods sold. Cost of goods sold increased at a rate lower than sales due to price increases effective January 1, 2026 and manufacturing efficiencies obtained during the period, partially offset by the shift of depreciation and building related expenses related to our 33 Caddie facility (formerly associated with Re-Tain<sup>®</sup>) from product development expense as a result of the Company's December 2025 decision to cease its focus on obtaining FDA approval of Re-Tain<sup>®</sup> and instead refit the facility for use in producing First Defense<sup>®</sup> products.

.

*Sales and Marketing Expenses*

During the three months ended March 31, 2026, sales and marketing expenses increased by 43.9%, or $0.4 million, to $1.2 million in comparison to $0.9 million during the three months ended March 31, 2025. This increase was primarily due to higher wages, including share-based compensation, and expenses associated with new and backfilled sales positions, coupled with increased promotional and tradeshow related expenses. In the three months ended March 31, 2025, we restricted commercial spending due to tight product supply; however, this tight supply was alleviated in the summer of 2025.

*Administrative Expenses*

During the three months ended March 31, 2026, administrative expenses increased by 82.7%, or $0.5 million, to $1.1 million in comparison to $0.6 million during the three months ended March 31, 2025. The increase was primarily due to a $0.4 million increase in executive compensation (including share-based compensation).

*Product Development Expenses*

During the three months ended March 31, 2026, product development expenses decreased by 58.0%, or $0.4 million, to $0.3 million in comparison to $0.8 million during the three months ended March 31, 2025. This decrease was driven by the $0.3 million shift to costs of goods sold of depreciation and building related expenses related to our 33 Caddie facility (formerly associated with Re-Tain<sup>®</sup>) as part of our recently announced strategy to utilize the facility for the production of First Defense<sup>®</sup> as a result of the Company's December 2025 decision to cease its focus on obtaining FDA approval of Re-Tain<sup>®</sup> and instead refit the facility for use in producing First Defense<sup>®</sup> products, coupled with a reduction of wages associated with Re-Tain<sup>®</sup> product development.

*Other (Expense) Income, Net* 

During the three months ended March 31, 2026, other expense, net was $15,187 in comparison to $0.3 million of other income, net during the three months ended March 31, 2025. The year-over-year net shift of 104.6% or $0.3 million was primarily due to a one-time insurance settlement of $0.4 million which occurred in the three months ended March 31, 2025.

*Income Tax Expense*

During both the three months ended March 31, 2026 and 2025, we recorded insignificant amounts of income tax expense.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 17

------

[**Table of Contents**](#toc)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ImmuCell Corporation

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Liquidity and Capital Resources**

Our sources of liquidity and capital resources are cash flows from operations, proceeds from our sale of common stock, and borrowings available under our bank line of credit.

We had aggregate debt outstanding (net of debt issuance and debt discount costs) of $8.7 million and $9.1 million as of March 31, 2026 and December 31, 2025, respectively. Recurring debt principal repayments (excluding the line of credit) aggregated $0.4 million during both the three months ended March 31, 2026 and 2025. We anticipate that recurring debt principal repayments will aggregate approximately $1.6 million during the year ending December 31, 2026. Our $1.0 million line of credit, which bears interest at the National Prime Rate per annum, is currently available until September 11, 2026. No draw on our line of credit was outstanding as of March 31, 2026, or December 31, 2025.

Interest expense (excluding amortization of debt issuance and debt discount costs) was approximately $97,000 and $117,000 during the three months ended March 31, 2026, and 2025, respectively. Our debt bears interest at fixed rates, which on a blended basis amounts to 4.3% per annum. We anticipate that interest expense (excluding amortization of debt issuance and debt discount costs) will be $367,000 during the year ending December 31, 2026.

In April of 2024, we entered into our ATM Agreement, which allows us to offer and sell up to $11 million of shares of our common stock. As of March 31, 2026, we have the capacity to sell $6 million of shares under the ATM Agreement but no pending plan to issue additional shares under that arrangement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The table below summarizes the changes in selected key accounts:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **As of** | **As of** | **Increase** | **Increase** |
|  | **March 31, 2026** | **December 31, 2025** | **Amount** | **Percent** |
| Cash and cash equivalents | $6812637 | $3806831 | $3005806 | 79% |
| Net working capital | $14948946 | $12966625 | $1982321 | 15% |
| Total assets | $44108374 | $42532447 | $1575927 | 4% |
| Stockholders' equity | $29135040 | $27055480 | $2079560 | 8% |
| Common shares outstanding<sup>(1)</sup> | 9046799 | 9045851 | 948 | 0% |

---

<sup>(1)</sup> There were 1,076,260 and 801,760 shares of common stock reserved for issuance for stock options that were outstanding as of March 31, 2026 and December 31, 2025, respectively.

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
|  | **2026** | **2025** |
| Net cash provided by operating activities | $3573031 | $1573836 |
| Net cash used for investing activities | $(167230) | $(329050) |
| Net cash used for financing activities | $(399995) | $(403647) |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Net cash provided by operating activities increased $2.0 million during the three months ended March 31, 2026 as compared to the three months ended March 31, 2025. The increase was primarily due to a $0.5 million increase in net income, $0.8 million less cash used for inventory, $0.4 million less cash used for accounts payable and accrued expenses, and $0.3 million additional cash provided by accounts receivable.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Net cash used for investing activities decreased $0.2 million during the three months ended March 31, 2026 as compared to the three months ended March 31, 2025. The decrease was primarily due to a reduction in capital expenditures.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Net cash used for financing activities decreased an insignificant amount during the three months ended March 31, 2026 as compared to the three months ended March 31, 2025.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Commitments, Contingencies and Contractual Obligations**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For disclosures on contingencies, see Note 9 "Commitments and Contingencies," of the Notes to Condensed Unaudited Financial Statements included in Part I, Item 1 of this Form 10-Q.

**Critical Accounting Policies and Estimates**&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

Our Financial Statements are prepared in accordance with U.S. GAAP, which require us to make certain complex estimates in the application of our accounting policies based on the best assumptions, judgments, and opinions of our management. There have been no significant changes to our critical accounting policies and estimates. For a description of our critical accounting policies, see Item 7., "Management's Discussion and Analysis of Financial Condition and Results of Operations," in our Annual Report on Form 10-K for the year ended December 31, 2025.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 18

------

[**Table of Contents**](#toc)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ImmuCell Corporation

**ITEM 3 - QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK**

Not applicable

**ITEM 4 - CONTROLS AND PROCEDURES**

*Disclosure Controls and Procedures:* Disclosure controls and procedures are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is (i) recorded, processed, summarized and reported, within the time periods specified in the SEC's rules and forms and (ii) accumulated and communicated to our management, including our principal executive and principal financial officer, as appropriate to allow timely decisions regarding required disclosures. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. Our management evaluated the effectiveness of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the Exchange Act)) as of March 31, 2026. Based on this evaluation, management concluded that our disclosure controls and procedures were effective as of that date.

*Changes in Internal Controls over Financial Reporting:* Our Chief Financial Officer, other members of management, and our accounting team periodically evaluate any change in internal control over financial reporting which has occurred during the prior fiscal quarter. We have concluded that there was no change in our internal control over financial reporting that occurred during the quarter ended March 31, 2026 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

**PART II: OTHER INFORMATION**

**ITEM 1 - LEGAL PROCEEDINGS**

In the ordinary course of business, we may become subject to lawsuits, investigations and claims. Although we cannot predict with certainty the ultimate resolution of any such lawsuits, investigations and claims against us, we do not believe that any pending or threatened legal proceedings to which we are or could become a party will have a material adverse effect on our business, results of operations, or financial condition.

**ITEM 1A - RISK FACTORS**

There have been no material changes to the risk factors identified in our Annual Report on Form 10-K for the year ended December 31, 2025, in response to Item 1A., "Risk Factors," of Part I of the Annual Report.

**ITEM 2 - UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS**

None

**ITEM 3 - DEFAULTS UPON SENIOR SECURITIES**

None

**ITEM 4 - MINE SAFETY DISCLOSURES**

None

**ITEM *5* - OTHER INFORMATION**

None

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *19*

------

[**Table of Contents**](#toc)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ImmuCell Corporation

**ITEM 6** – **EXHIBITS**

---

| | |
|:---|:---|
| Exhibit 10.1+ | [<u>Employment Agreement between the Company and Timothy C. Fiori dated as of January 27, 2026 (incorporated by reference to Exhibit 10.1 of Current Report on Form 8-K filed February 2, 2026).</u>](http://www.sec.gov/Archives/edgar/data/811641/000143774926002685/ex_915264.htm) |
| Exhibit 10.2+ | [<u>Employment Agreement between the Company and Bobbi Jo Brockmann dated as of January 27, 2026 (incorporated by reference to Exhibit 10.2 of Current Report on Form 8-K filed February 2, 2026).</u>](http://www.sec.gov/Archives/edgar/data/811641/000143774926002685/ex_915265.htm) |
| Exhibit 10.3+ | [<u>Performance-Based Incentive Stock Option Agreement between the Company and Paul Olivier te Boekhorst (incorporated by reference to Exhibit 10.3 of Current Report on Form 8-K filed February 2, 2026)</u>.](http://www.sec.gov/Archives/edgar/data/811641/000143774926002685/ex_915266.htm) |
| Exhibit 31.1<sup>\*</sup> | [Certification of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](ex_908800.htm) |
| Exhibit 31.2<sup>\*</sup> | [Certification of the President and Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](ex_908801.htm) |
| Exhibit 32.1<sup>\*</sup> | [Certification of the Chief Financial Officer pursuant to Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](ex_908802.htm) |
| Exhibit 32.2<sup>\*</sup> | [Certification of the President and Chief Executive Officer pursuant to Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](ex_908803.htm) |
| 101.INS<sup>\*</sup> | Inline XBRL Instance Document-the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. |
| 101.SCH<sup>\*</sup> | Inline XBRL Taxonomy Extension Schema Document. |
| 101.CAL<sup>\*</sup> | Inline XBRL Taxonomy Extension Calculation Linkbase Document. |
| 101.DEF<sup>\*</sup> | Inline XBRL Taxonomy Extension Definition Linkbase Document. |
| 101.LAB<sup>\*</sup> | Inline XBRL Taxonomy Extension Label Linkbase Document. |
| 101.PRE<sup>\*</sup> | Inline XBRL Taxonomy Extension Presentation Linkbase Document. |
| 104<sup>\*</sup> | Cover Page Interactive Data File-the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. |
| +Management contract or compensatory plan or arrangement. | +Management contract or compensatory plan or arrangement. |
| <sup>\*</sup>Filed herewith. | <sup>\*</sup>Filed herewith. |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 20

------

[**Table of Contents**](#toc)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ImmuCell Corporation

**SIGNATURE**

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | |
|:---|:---|
|  | <u>ImmuCell Corporation</u> |
|  | Registrant |
| Date: May 14, 2026 | By: <u>/s/ Timothy C. Fiori</u> |
|  | Timothy C. Fiori |
|  | Chief Financial Officer and |
|  | Principal Financial Officer |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 21

## Exhibit 31.1

**Exhibit 31.1**

**CERTIFICATION PURSUANT TO REQUIRED BY RULE 13a-14(a)**

I, Timothy C. Fiori, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of ImmuCell Corporation (the Company);

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report;

4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Company and have:

a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the Company is made known to me by others within the Company, particularly during the period in which this report is being prepared;

b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) evaluated the effectiveness of the Company's disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) disclosed in this report any change in the Company's internal control over financial reporting that occurred during the Company's most recent fiscal quarter (the Company's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting; and

5. I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the Company's auditors and the audit committee of the Company's Board of Directors (or persons performing the equivalent function):

a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company's ability to record, process, summarize and report financial information; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the Company's internal control over financial reporting.

Date: May 14, 2026

---

| |
|:---|
| <u>/s/ Timothy C. Fiori</u> |
| Timothy C. Fiori |
| Chief Financial Officer |

---

## Exhibit 31.2

**Exhibit 31.2**

**CERTIFICATION PURSUANT TO REQUIRED BY RULE 13a-14(a)**

I, Paul Olivier te Boekhorst , certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of ImmuCell Corporation (the Company);

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report;

4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Company and have:

a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the Company is made known to me by others within the Company, particularly during the period in which this report is being prepared;

b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) evaluated the effectiveness of the Company's disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) disclosed in this report any change in the Company's internal control over financial reporting that occurred during the Company's most recent fiscal quarter (the Company's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting; and

5. I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the Company's auditors and the audit committee of the Company's Board of Directors (or persons performing the equivalent function):

a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company's ability to record, process, summarize and report financial information; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the Company's internal control over financial reporting.

Date: May 14, 2026

<u>/s/ Paul Olivier te Boekhorst</u>

Paul Olivier te Boekhorst

President and Chief Executive Officer

## Exhibit 32.1

**Exhibit 32.1**

**CERTIFICATION PURSUANT TO SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF**

**THE SARBANES- OXLEY ACT OF 2002**

In connection with the Quarterly Report on Form 10-Q of ImmuCell Corporation (the "Company") for the quarter ended March 31, 2026, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Timothy C. Fiori, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

&nbsp;&nbsp;&nbsp;&nbsp;(1) the Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended (the "Exchange Act"); and

&nbsp;&nbsp;&nbsp;&nbsp;(2) the information contained in the Report fairly presents, in all material respects, the financial condition, results of operations and cash flows of the Company.

This certification is provided pursuant to 18 U.S.C. Section 1350 and Item 601(b)(32) of Regulation S-K ("Item 601(b)(32)") promulgated under the Securities Act of 1933, as amended (the "Securities Act"), and the Exchange Act. In accordance with clause (ii) of Item 601(b)(32), this certification (A) shall not be deemed "filed" for the purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, and (B) shall not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.

---

| |
|:---|
| <u>/s/ Timothy C. Fiori</u> |
| Timothy C. Fiori |
| Chief Financial Officer |
| May 14, 2026 |

---

A signed original of this written statement required by Section 906 has been provided to ImmuCell Corporation and will be retained by ImmuCell Corporation and furnished to the Securities and Exchange Commission or its staff upon request.

## Exhibit 32.2

**Exhibit 32.2**

**CERTIFICATION PURSUANT TO SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF** 

**THE SARBANES- OXLEY ACT OF 2002**

In connection with the Quarterly Report on Form 10-Q of ImmuCell Corporation (the "Company") for the quarter ended March 31, 2026, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Paul Olivier te Boekhorst, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

&nbsp;&nbsp;&nbsp;&nbsp;(1) the Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended (the "Exchange Act"); and

&nbsp;&nbsp;&nbsp;&nbsp;(2) the information contained in the Report fairly presents, in all material respects, the financial condition, results of operations and cash flows of the Company.

This certification is provided pursuant to 18 U.S.C. Section 1350 and Item 601(b)(32) of Regulation S-K ("Item 601(b)(32)") promulgated under the Securities Act of 1933, as amended (the "Securities Act"), and the Exchange Act. In accordance with clause (ii) of Item 601(b)(32), this certification (A) shall not be deemed "filed" for the purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, and (B) shall not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.

<u>/s/ Paul Olivier te Boekhorst</u>

Paul Olivier te Boekhorst

President and Chief Executive Officer

May 14, 2026

A signed original of this written statement required by Section 906 has been provided to ImmuCell Corporation and will be retained by ImmuCell Corporation and furnished to the Securities and Exchange Commission or its staff upon request.